Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pharmather Hldgs Ltd
(OP:
PHRRF
)
0.1888
-0.0102 (-5.13%)
Streaming Delayed Price
Updated: 12:39 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pharmather Hldgs Ltd
< Previous
1
2
3
Next >
Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
October 05, 2022
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine
Via
Benzinga
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
October 05, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
September 29, 2022
PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.
Via
Benzinga
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
September 29, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
September 17, 2022
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced...
Via
Benzinga
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
September 07, 2022
PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and...
Via
Benzinga
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
July 13, 2022
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S.
Via
Benzinga
PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing
June 29, 2022
Ketamine-producer PharmaTher Holdings Ltd. (OTCQB: PHRRF) has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET...
Via
Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
June 02, 2022
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its...
Via
Benzinga
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
May 26, 2022
PharmaTher Holdings Ltd. (OTC: PHRRF) continues on its path to becoming the leader in specialty ketamine products.
Via
Benzinga
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
May 10, 2022
Psychedelics policy action took center stage this week.
Via
Benzinga
Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process
May 05, 2022
The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process.
Via
Benzinga
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
May 02, 2022
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.
Via
Benzinga
Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy
April 26, 2022
Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.
Via
Benzinga
Ketamine Could Help Treat Parkinson's Disease, Study Finds
March 24, 2022
PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced positive results from a clinical study of ketamine for the treatment of ...
Via
Benzinga
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
January 25, 2022
This article was originally published on Micr...
Via
Benzinga
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
January 12, 2022
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced...
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Exposures
Product Safety
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
October 11, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
October 04, 2021
The Week In Psychedelics:
Via
Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
September 22, 2021
Via
FinancialNewsMedia
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
These OTC Securities Had the Most Trading Activity in June
July 20, 2021
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
How To Invest In "Magic Mushrooms" (Psychedelics)
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
July 02, 2021
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...
Via
Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
June 30, 2021
Institutional analysts are taking a liking to the industry ...
Via
Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
May 24, 2021
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:
Via
Benzinga
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading
April 26, 2021
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ...
Via
Benzinga
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
April 14, 2021
Via
FinancialNewsMedia
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.